{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:04:26Z","timestamp":1791201866810,"version":"4.2.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s10549-013-2689-5","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T03:56:40Z","timestamp":1381118200000},"page":"437-446","source":"Crossref","is-referenced-by-count":58,"title":["A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy"],"prefix":"10.1007","volume":"141","author":[{"given":"Sara A.","family":"Hurvitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"O\u2019Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne C.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gligorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haresh","family":"Jhangiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid R.","family":"Mirshahidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tan-Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"El-Hashimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Lincy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetiana","family":"Taran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Sahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,8]]},"reference":[{"issue":"8","key":"2689_CR1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2007.14.8197","volume":"27","author":"G Sauter","year":"2009","unstructured":"Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27(8):1323\u20131333. doi: 10.1200\/JCO.2007.14.8197","journal-title":"J Clin Oncol"},{"issue":"4905","key":"2689_CR2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712","journal-title":"Science"},{"issue":"3","key":"2689_CR3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ctrv.2012.04.008","volume":"39","author":"SA Hurvitz","year":"2013","unstructured":"Hurvitz SA, Hu Y, O\u2019Brien N, Finn RS (2013) Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 39(3):219\u2013229. doi: 10.1016\/j.ctrv.2012.04.008","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2689_CR4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4):320\u2013368. doi: 10.1634\/theoncologist.2008-0230","journal-title":"Oncologist"},{"issue":"Suppl 3","key":"2689_CR5","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.3816\/CBC.2010.s.015","volume":"10","author":"R Nahta","year":"2010","unstructured":"Nahta R, O\u2019Regan RM (2010) Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K\/Akt\/mTOR pathway. Clin Breast Cancer 10(Suppl 3):S72\u2013S78. doi: 10.3816\/CBC.2010.s.015","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"2689_CR6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"issue":"5","key":"2689_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1758834012451205","volume":"4","author":"SA Hurvitz","year":"2012","unstructured":"Hurvitz SA, Kakkar R (2012) The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol 4(5):235\u2013245. doi: 10.1177\/1758834012451205","journal-title":"Ther Adv Med Oncol"},{"key":"2689_CR8","first-page":"62","volume":"2","author":"T Vu","year":"2012","unstructured":"Vu T, Claret FX (2012) Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2:62. doi: 10.3389\/fonc.2012.00062","journal-title":"Front Oncol"},{"issue":"18","key":"2689_CR9","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","volume":"24","author":"N Robert","year":"2006","unstructured":"Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786\u20132792","journal-title":"J Clin Oncol"},{"issue":"4","key":"2689_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3747\/co.v16i4.469","volume":"16","author":"S Dent","year":"2009","unstructured":"Dent S, Verma S, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, Wang B, Pritchard K (2009) The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer. Curr Oncol 16(4):25\u201335","journal-title":"Curr Oncol"},{"issue":"1","key":"2689_CR11","first-page":"19","volume":"1","author":"R Bartsch","year":"2007","unstructured":"Bartsch R, Wenzel C, Steger GG (2007) Trastuzumab in the management of early and advanced stage breast cancer. Biologics 1(1):19\u201331","journal-title":"Biologics"},{"issue":"11","key":"2689_CR12","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1634\/theoncologist.2011-0165","volume":"16","author":"H Wong","year":"2011","unstructured":"Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C, Yau T (2011) Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2(+) metastatic breast cancer. Oncologist 16(11):1535\u20131546. doi: 10.1634\/theoncologist.2011-0165","journal-title":"Oncologist"},{"key":"2689_CR13","first-page":"415170","volume":"2012","author":"AL Wong","year":"2012","unstructured":"Wong AL, Lee SC (2012) Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 2012:415170. doi: 10.1155\/2012\/415170","journal-title":"Int J Breast Cancer"},{"issue":"7","key":"2689_CR14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489\u2013501","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"2689_CR15","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","volume":"13","author":"CH Lu","year":"2007","unstructured":"Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13(19):5883\u20135888","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2689_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117\u2013127","journal-title":"Cancer Cell"},{"issue":"6","key":"2689_CR17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529. doi: 10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"key":"2689_CR18","unstructured":"Novartis Pharmaceuticals Corporation (2012) Afinitor (everolimus) prescribing information. East Hanover, NJ. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/afinitor.pdf . Accessed 20 Mar 2013"},{"issue":"34","key":"2689_CR19","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","volume":"28","author":"F Andre","year":"2010","unstructured":"Andre F, Campone M, O\u2019Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28(34):5110\u20135115. doi: 10.1200\/JCO.2009.27.8549","journal-title":"J Clin Oncol"},{"issue":"10","key":"2689_CR20","first-page":"E279","volume":"91","author":"F Janku","year":"2004","unstructured":"Janku F, Pribylova O, Zimovjanova M, Pazdrova G, Safanda M, Zemanova M, Petruzelka L (2004) 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2\/neu overexpressing advanced breast cancer: single institution prospective study. Bull Cancer 91(10):E279\u2013E283","journal-title":"Bull Cancer"},{"issue":"20","key":"2689_CR21","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/1078-0432.CCR-04-0112","volume":"10","author":"X Zhou","year":"2004","unstructured":"Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D (2004) Activation of the Akt\/mammalian target of rapamycin\/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10(20):6779\u20136788","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2689_CR22","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1158\/1078-0432.CCR-12-1785","volume":"18","author":"S Chandarlapaty","year":"2012","unstructured":"Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA (2012) Frequent mutational activation of the PI3K\u2013AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 18(24):6784\u20136791. doi: 10.1158\/1078-0432.CCR-12-1785","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2689_CR23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10549-012-2252-9","volume":"136","author":"AM Jegg","year":"2012","unstructured":"Jegg AM, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R, Pegram MD (2012) PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Res Treat 136(3):683\u2013692. doi: 10.1007\/s10549-012-2252-9","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2689_CR24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/187152012799015002","volume":"12","author":"SS Gayle","year":"2012","unstructured":"Gayle SS, Arnold SL, O\u2019Regan RM, Nahta R (2012) Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. Anticancer Agents Med Chem 12(2):151\u2013162","journal-title":"Anticancer Agents Med Chem"},{"key":"2689_CR25","unstructured":"U.S. Food and Drug Administration (2012) FDA approves Perjeta for type of late-stage breast cancer [news release]. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm307549.htm . Accessed 20 March 2013"},{"key":"2689_CR26","doi-asserted-by":"crossref","unstructured":"Baselga J, Cort\u00e9s J, Im S-A, Clark E, Kiermaier A, Ross G, Swain SM (2012) Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Presented at CTRC-AACR San Antonio breast cancer symposium, December 4\u20138, 2012, San Antonio, TX. Abstract S5-1","DOI":"10.1158\/0008-5472.SABCS12-S5-1"},{"issue":"23","key":"2689_CR27","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","volume":"29","author":"PK Morrow","year":"2011","unstructured":"Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nunez R, Hortobagyi GN, Yu D, Esteva FJ (2011) Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29(23):3126\u20133132. doi: 10.1200\/JCO.2010.32.2321","journal-title":"J Clin Oncol"},{"issue":"18","key":"2689_CR28","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256\u20134265. doi: 10.1002\/cncr.25219","journal-title":"Cancer"},{"key":"2689_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/CMO.S7319","volume":"6","author":"PE Oberstein","year":"2012","unstructured":"Oberstein PE, Saif MW (2012) Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 6:41\u201351. doi: 10.4137\/CMO.S7319","journal-title":"Clin Med Insights Oncol"},{"issue":"11","key":"2689_CR30","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2009.26.2923","volume":"28","author":"T Doi","year":"2010","unstructured":"Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28(11):1904\u20131910. doi: 10.1200\/JCO.2009.26.2923","journal-title":"J Clin Oncol"},{"key":"2689_CR31","doi-asserted-by":"crossref","unstructured":"O\u2019Regan R, Ozguroglu M, Andre F, Toi M, Jerusalem G, Wilks S, Isaacs C, Xu B, Masuda N, Arena FP, Yardley D, Yap YS, Mukhopadhyay P, Douma S, El-Hashimy M, Taran T, Sahmoud T, Lebwohl D, Gianni L (2013) Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). Presented at 2013 ASCO annual meeting, May 31\u2013June 4, 2013, Chicago, IL. Abstract 505","DOI":"10.1200\/jco.2013.31.15_suppl.505"},{"key":"2689_CR32","doi-asserted-by":"crossref","unstructured":"Paplomata E, Zelnak A, O\u2019Regan R (2013) Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat 140(3):453\u2013462","DOI":"10.1007\/s10549-013-2630-y"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2689-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2689-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T10:51:47Z","timestamp":1596624707000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2689-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["2689"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2689-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}